Talis Biomedical (TLIS) Competitors

Lucid Diagnostics (NASDAQ:LUCD) and Talis Biomedical (NASDAQ:TLIS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking.

Does the MarketBeat Community prefer LUCD or TLIS?

Lucid Diagnostics received 19 more outperform votes than Talis Biomedical when rated by MarketBeat users. Likewise, 62.22% of users gave Lucid Diagnostics an outperform vote while only 37.50% of users gave Talis Biomedical an outperform vote.

Company	Underperform	Outperform
Lucid Diagnostics	Outperform Votes 28 62.22%	Underperform Votes 17 37.78%
Talis Biomedical	Outperform Votes 9 37.50%	Underperform Votes 15 62.50%

Which has higher earnings and valuation, LUCD or TLIS?

Lucid Diagnostics has higher revenue and earnings than Talis Biomedical. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Talis Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$2.43M	16.53	-$52.67M	-$1.27	-0.61
Talis Biomedical	$348K	47.91	-$62.01M	-$31.43	-0.29

Which has more volatility & risk, LUCD or TLIS?

Lucid Diagnostics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Talis Biomedical has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Does the media favor LUCD or TLIS?

In the previous week, Lucid Diagnostics had 2 more articles in the media than Talis Biomedical. MarketBeat recorded 2 mentions for Lucid Diagnostics and 0 mentions for Talis Biomedical. Lucid Diagnostics' average media sentiment score of 0.00 beat Talis Biomedical's score of -0.67 indicating that Talis Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Lucid Diagnostics	Negative
Talis Biomedical	Neutral

Do analysts recommend LUCD or TLIS?

Lucid Diagnostics currently has a consensus target price of $4.33, suggesting a potential upside of 462.04%. Talis Biomedical has a consensus target price of $5.00, suggesting a potential downside of 45.36%. Given Talis Biomedical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Talis Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Talis Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Do institutionals and insiders believe in LUCD or TLIS?

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 43.8% of Talis Biomedical shares are held by institutional investors. 4.8% of Lucid Diagnostics shares are held by company insiders. Comparatively, 46.0% of Talis Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Is LUCD or TLIS more profitable?

Lucid Diagnostics has a net margin of -1,576.60% compared to Lucid Diagnostics' net margin of -5,784.73%. Lucid Diagnostics' return on equity of -75.40% beat Talis Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-1,576.60%	-901.79%	-106.33%
Talis Biomedical	-5,784.73%	-75.40%	-56.16%

Summary

Lucid Diagnostics beats Talis Biomedical on 11 of the 18 factors compared between the two stocks.